Prescription Description
| Prescription ID | TCMF654 |
| Pinyin Name | Ru He San Jie Pian |
| Chinese Name | ä¹³æ ¸æ•£ç»“ç‰‡ |
| English Name | Ru He San Jie Tablet |
| Function Description | 乳癖, ä¹³æ ¸ |
| Indications | Breast lump disorder |
| Disease ICD-11 Category |
SC24 [Breast lump disorder (TM1), 乳癖 (TM1)
]; |
| Human Tissues Associated with Indication | Breast |
| Reference | Chinese pharmacopoeia (2015) |
| Reference Book/link | ISBN 978-7-5067-7337-9 |
Prescription Components
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH228 | Bupleurum chinense | 柴胡 | TCMH228 | ITSAM2218-14 |
| TCMH421 | Angelica sinensis | 当归 | TCMH421 | ITSAF173-14 |
| TCMH981 | Astragalus membranaceus | 黄芪 | TCMH981 | ITSAK2981-14 |
| TCMH720 | Tulipa edulis | å…‰æ…ˆè‡ | TCMH720 | GBVT2777-13, GBVP2304-14 |
| TCMH1331 | Rhaponticum uniflorum | æ¼èŠ¦ | TCMH1331 | ITSAJ4341-14 |
| TCMH1226 | Laminaria japonica | 昆布 | TCMH1226 | AB022790 |
| TCMH797 | Sargassum | æµ·è—» | TCMH797 | |
| TCMH1359 | Pyrola calliantha | é¹¿è¡”è‰ | TCMH1359 | FJ378582 |
| TCMH2532 | Curcuma aromatica | éƒé‡‘ | TCMH2532 | ITSAF2298-14 |
| TCMH2507 | Epimedium brevicornum | 淫羊藿 | TCMH2507 | AY362429 |
Targeted Human Proteins by the Ingredients of Prescription
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT102 | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | Hydrolase | P24666 |
| TCMT103 | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | Hydrolase | P10586 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT130 | ALOX5 | Arachidonate 5-lipoxygenase | Oxidoreductase | P09917 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT139 | CA6 | Carbonic anhydrase VI | Lyase | P23280 |
| TCMT140 | CA5B | Carbonic anhydrase VB | Lyase | Q9Y2D0 |
| TCMT141 | CA5A | Carbonic anhydrase VA | Lyase | P35218 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT150 | RORC | Nuclear receptor ROR-gamma | Nuclear receptor | P51449 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT161 | HCAR2 | Hydroxycarboxylic acid receptor 2 | GPCR | Q8TDS4 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT187 | AR | Androgen Receptor | Nuclear receptor | P10275 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT193 | RELA | Nuclear factor NF-kappa-B p65 subunit | Transcription factor | Q04206 |
| TCMT194 | MAP3K7 | Mitogen-activated protein kinase kinase kinase 7 | Kinase | O43318 |
| TCMT195 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Kinase | Q02750 |
| TCMT196 | MAP2K7 | Dual specificity mitogen-activated protein kinase kinase 7 | Kinase | O14733 |
| TCMT206 | CYP2A6 | Cytochrome P450 2A6 | Oxidoreductase | P11509 |
| TCMT208 | MAOA | Monoamine oxidase A | Oxidoreductase | P21397 |
| TCMT212 | SRC | Tyrosine-protein kinase SRC | Kinase | P12931 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT217 | CYP2C8 | Cytochrome P450 2C8 | Oxidoreductase | P10632 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT230 | HSD17B3 | Estradiol 17-beta-dehydrogenase 3 | Oxidoreductase | P37058 |
| TCMT239 | PIM1 | Serine/threonine-protein kinase PIM1 | Kinase | P11309 |
| TCMT240 | AMY1A | Salivary alpha-amylase | Unclassified | P04745 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT260 | FLT3 | Tyrosine-protein kinase receptor FLT3 | Kinase | P36888 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT268 | CYP2A13 | Cytochrome P450 2A13 | Oxidoreductase | Q16696 |
| TCMT295 | MMP1 | Matrix metalloproteinase-1 | Hydrolase | P03956 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT301 | PTGES | Prostaglandin E synthase | Isomerase | O14684 |
| TCMT306 | MMP2 | Matrix metalloproteinase-2 | Hydrolase | P08253 |
| TCMT321 | MMP9 | Matrix metalloproteinase 9 | Hydrolase | P14780 |
| TCMT322 | MMP13 | Matrix metalloproteinase 13 | Hydrolase | P45452 |
| TCMT369 | IGF1R | Insulin-like growth factor I receptor | Kinase | P08069 |
| TCMT370 | KDR | Vascular endothelial growth factor receptor 2 | Kinase | P35968 |
| TCMT374 | AURKB | Serine/threonine-protein kinase Aurora-B | Kinase | Q96GD4 |
| TCMT388 | AXL | Tyrosine-protein kinase receptor UFO | Kinase | P30530 |
| TCMT401 | MET | Hepatocyte growth factor receptor | Kinase | P08581 |
| TCMT422 | CAMK2B | CaM kinase II beta | Kinase | Q13554 |
| TCMT445 | NEK2 | Serine/threonine-protein kinase NEK2 | Kinase | P51955 |
| TCMT45 | APP | Beta amyloid A4 protein | Unclassified | P05067 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT462 | NEK6 | Serine/threonine-protein kinase NEK6 | Kinase | Q9HC98 |
| TCMT479 | AKT1 | Serine/threonine-protein kinase AKT | Kinase | P31749 |
| TCMT484 | PLK1 | Serine/threonine-protein kinase PLK1 | Kinase | P53350 |
| TCMT560 | F10 | Coagulation factor X | Unclassified | P00742 |
| TCMT565 | EP300 | Histone acetyltransferase p300 | Transferase | Q09472 |
| TCMT566 | NOS2 | Nitric oxide synthase, inducible | Oxidoreductase | P35228 |
| TCMT570 | ANPEP | Aminopeptidase N | Unclassified | P15144 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT598 | TOP1 | DNA topoisomerase I | Isomerase | P11387 |
| TCMT599 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Transferase | P61088 |
| TCMT614 | EGLN1 | Egl nine homolog 1 | Oxidoreductase | Q9GZT9 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT690 | HDAC3 | Histone deacetylase 3 | Hydrolase | O15379 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT725 | CACNA1C | Voltage-gated L-type calcium channel alpha-1C subunit | Ion channel | Q13936 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT784 | AVPR2 | Vasopressin V2 receptor | GPCR | P30518 |
| TCMT785 | CXCR1 | Interleukin-8 receptor A | GPCR | P25024 |
| TCMT786 | CCR4 | C-C chemokine receptor type 4 | GPCR | P51679 |
| TCMT791 | PKN1 | Protein kinase N1 | Kinase | Q16512 |
| TCMT793 | PYGL | Liver glycogen phosphorylase | Transferase | P06737 |
| TCMT80 | MAPK1 | MAP kinase ERK2 | Kinase | P28482 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT87 | CYP2C9 | Cytochrome P450 2C9 | Oxidoreductase | P11712 |
| TCMT99 | SHBG | Testis-specific androgen-binding protein | Unclassified | P04278 |
Targeted Pathogenic Microbes by the Ingredients of Prescription
| Target ID | Target Name |
|---|---|
| TCMT1178 | Actinomyces viscosus |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1190 | Plasmodium falciparum (isolate FcB1 / Columbia) |
| TCMT1208 | Escherichia coli K12 |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1210 | Streptococcus sobrinus |
| TCMT1211 | Fusobacterium nucleatum |
| TCMT1212 | Verticillium dahliae |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1221 | Human herpesvirus 4 |
| TCMT1222 | Plasmodium falciparum D6 |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1243 | Aspergillus flavus |
| TCMT1245 | Phytophthora cactorum |
| TCMT1246 | Escherichia coli |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1313 | Human immunodeficiency virus 2 |
| TCMT1314 | Streptococcus viridans |
| TCMT1321 | Staphylococcus hominis |
| TCMT1343 | Staphylococcus simulans |
| TCMT1344 | Staphylococcus sciuri |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1370 | Prevotella melaninogenica |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1384 | Fusarium tricinctum |
| TCMT1408 | Colletotrichum gloeosporioides |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1444 | Fusarium oxysporum |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
Gene Ontology Associated to Targeted Human Proteins
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 12.6946 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 11.6988 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, ALOX5, APP, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FUT7, HSD17B3, PIM1, PPARA, PTGES, XDH | 8.83506 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, ALOX5, APP, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FABP4, FUT7, HSD17B1, HSD17B3, MET, PPARA, PTGES | 7.17418 |
| [BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, APP, AR, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 6.61208 |
| [BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, APP, AR, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 6.60878 |
| [BP] GO:0010035 | response to inorganic substance | AKR1B1, APP, AXL, CA2, CYP1A1, CYP1A2, CYP1B1, FABP4, KDR, MMP9, PTGES, RELA, SRC | 6.33061 |
| [BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, ALOX5, APP, AR, AURKB, AXL, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FABP3, FABP4, FLT3, FUT7, HSD17B1, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, PTGES, RELA, RORC, SRC, TOP1, XDH | 6.23256 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, FABP3, PPARA | 5.75886 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 5.47363 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, ALOX5, APP, AR, AURKB, AXL, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, FABP3, FABP4, FLT3, FUT7, HSD17B1, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP1, MMP2, PIM1, PPARA, PTGES, RELA, RORC, SRC, TOP1, XDH | 5.40125 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, APP, AR, AXL, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, IGF1R, MMP2, MMP9, PPARA, PTGES, RELA, RORC, SRC | 5.27419 |
| [BP] GO:1902533 | positive regulation of intracellular signal transduction | ADORA1, AKR1B1, APP, AR, AXL, CYP1B1, F10, F3, FLT3, KDR, MAP2K1, MAP3K7, MET, RELA, SRC, XDH | 5.27419 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 5.27419 |
| [BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, APP, AR, CSNK2A1, CYP1B1, F3, FABP3, FLT3, IGF1R, KDR, MAP2K1, MMP2, MMP9, PIM1, PTGES, RELA, SRC, XDH | 5.25678 |
| [BP] GO:0010941 | regulation of cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, CYP1B1, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MET, MMP9, PIM1, PPARA, RELA, SRC, XDH | 5.25112 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA12, CA2, CA7, CACNA1C, CYP19A1, CYP1A1, CYP1B1, F10, F3, FABP3, FABP4, FLT3, HCAR2, HSD17B1, HSD17B3, KDR, MAOA, MET, PPARA, SRC, XDH | 5.20658 |
| [BP] GO:0019369 | arachidonic acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 5.18734 |
| [BP] GO:0033559 | unsaturated fatty acid metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 5.14934 |
| [BP] GO:0043067 | regulation of programmed cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, CYP1B1, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MET, MMP9, PIM1, RELA, SRC, XDH | 5.04261 |
| [BP] GO:0006690 | icosanoid metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 4.9935 |
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, APP, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, HSD17B1, HSD17B3 | 4.78768 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, FABP3, PPARA | 4.78633 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, APP, AR, AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FLT3, IGF1R, KDR, MMP2, PPARA, PTGES, RELA, RORC, SRC | 4.69745 |
| [BP] GO:1902531 | regulation of intracellular signal transduction | ADORA1, AKR1B1, APP, AR, AURKB, AXL, CSNK2A1, CYP1B1, F10, F3, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 4.6455 |
| [BP] GO:0042221 | response to chemical | AKR1B1, APP, AR, AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FLT3, IGF1R, KDR, MMP2, MMP9, PPARA, PTGES, RELA, RORC, SRC, TOP1 | 4.49282 |
| [BP] GO:0033993 | response to lipid | AR, AXL, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, FABP3, FLT3, PTGES, RELA, RORC, SRC | 4.45403 |
| [BP] GO:0042981 | regulation of apoptotic process | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, CYP1B1, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MMP9, PIM1, RELA, SRC, XDH | 4.45403 |
| [BP] GO:0014070 | response to organic cyclic compound | APP, AR, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, PTGES, RELA, RORC, SRC | 4.43488 |
| [BP] GO:0009967 | positive regulation of signal transduction | ADORA1, AKR1B1, APP, AR, AXL, CSNK2A1, CYP1B1, F10, F3, FLT3, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 4.43488 |
| [BP] GO:0048513 | animal organ development | ACHE, AR, AXL, CA2, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, FLT3, HSD17B3, KDR, MAP2K1, PPARA, RELA, SRC | 4.36791 |
| [BP] GO:0006631 | fatty acid metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA, PTGES | 4.26437 |
| [BP] GO:0010646 | regulation of cell communication | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 4.02693 |
| [BP] GO:0060548 | negative regulation of cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, IGF1R, KDR, MET, MMP9, PIM1, PPARA, RELA, SRC | 4.00356 |
| [BP] GO:1901568 | fatty acid derivative metabolic process | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 4.00356 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, ALOX5, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, FABP4, FUT7, MET, PPARA, PTGES | 3.96062 |
| [BP] GO:0023051 | regulation of signaling | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1B1, F10, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP9, RELA, SRC, XDH | 3.96062 |
| [BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, F10, F3, FABP3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC, XDH | 3.92738 |
| [BP] GO:0001676 | long-chain fatty acid metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, PTGES | 3.88201 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, APP, AR, CA2, CA9, CSNK2A1, CYP1A2, FABP3, FLT3, IGF1R, MMP2, PPARA, RELA, SRC | 3.88155 |
| [BP] GO:0030522 | intracellular receptor signaling pathway | AR, MAP3K7, PIM1, PPARA, RELA, RORC, SRC | 3.71283 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, HSD17B1, HSD17B3 | 3.71283 |
| [BP] GO:0034614 | cellular response to reactive oxygen species | AKR1B1, AXL, CYP1B1, MMP9, RELA, SRC | 3.71283 |
| [BP] GO:0043069 | negative regulation of programmed cell death | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, IGF1R, KDR, MET, MMP9, PIM1, RELA, SRC | 3.69842 |
| [BP] GO:0009698 | phenylpropanoid metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.6325 |
| [BP] GO:0009804 | coumarin metabolic process | CYP1A1, CYP2A13, CYP2A6 | 3.6325 |
| [BP] GO:0048584 | positive regulation of response to stimulus | ADORA1, AKR1B1, APP, AR, AXL, CSNK2A1, CYP1B1, F10, F3, FABP4, FLT3, KDR, MAP2K1, MAP3K7, MET, MMP2, MMP9, RELA, SRC, XDH | 3.63083 |
| [BP] GO:0051270 | regulation of cellular component movement | ADORA1, ADORA3, APP, CACNA1C, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 3.61294 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, HSD17B1, HSD17B3 | 3.61294 |
| [BP] GO:0032879 | regulation of localization | ACHE, ADORA1, ADORA3, APP, AR, AXL, CA2, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1B1, F10, F3, HCAR2, IGF1R, KDR, MAP2K1, MET, MMP9, PPARA, SRC | 3.61294 |
| [BP] GO:0018108 | peptidyl-tyrosine phosphorylation | AXL, FLT3, IGF1R, KDR, MAP2K1, MET, SRC | 3.61294 |
| [BP] GO:0018212 | peptidyl-tyrosine modification | AXL, FLT3, IGF1R, KDR, MAP2K1, MET, SRC | 3.57211 |
| [BP] GO:0030334 | regulation of cell migration | ADORA1, ADORA3, APP, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 3.48939 |
| [BP] GO:0046777 | protein autophosphorylation | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1, SRC | 3.48332 |
| [BP] GO:0048518 | positive regulation of biological process | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA7, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, F10, F3, FABP3, FABP4, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC, XDH | 3.46854 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CACNA1C, CYP19A1, CYP1A1, CYP1B1, HCAR2, HSD17B1, HSD17B3 | 3.46854 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, AURKB, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, FABP3, FABP4, FUT7, MAOA, MMP1, MMP2, MMP9, SRC, XDH | 3.4651 |
| [BP] GO:0006468 | protein phosphorylation | APP, AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 3.45117 |
| [BP] GO:0050896 | response to stimulus | ACHE, ADORA1, ADORA3, AKR1B1, APP, AR, AURKB, AXL, CA2, CA6, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, F10, F3, FABP3, FABP4, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MMP2, MMP9, PPARA, PTGES, RELA, RORC, SRC, TOP1 | 3.36433 |
| [BP] GO:0009725 | response to hormone | AKR1B1, AR, CA2, CA9, CSNK2A1, CYP1A2, FABP3, FLT3, PPARA, RELA, SRC | 3.35789 |
| [BP] GO:0070887 | cellular response to chemical stimulus | AKR1B1, APP, AR, AXL, CYP1A1, CYP1A2, CYP1B1, FABP4, FLT3, IGF1R, KDR, MMP2, MMP9, RELA, RORC, SRC | 3.33748 |
| [BP] GO:2000145 | regulation of cell motility | ADORA1, ADORA3, APP, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 3.25332 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.22329 |
| [BP] GO:0043066 | negative regulation of apoptotic process | ADORA1, AKR1B1, AR, AURKB, AXL, CSNK2A1, IGF1R, KDR, MMP9, PIM1, RELA, SRC | 3.10196 |
| [BP] GO:0051716 | cellular response to stimulus | AKR1B1, APP, AR, AURKB, AXL, CA2, CA9, CYP1A1, CYP1A2, CYP1B1, FABP4, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MMP2, MMP9, RELA, RORC, SRC | 3.08378 |
| [BP] GO:0018193 | peptidyl-amino acid modification | AURKB, AXL, CSNK2A1, F10, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, SRC, TOP1 | 3.00243 |
| [BP] GO:0071310 | cellular response to organic substance | AKR1B1, APP, AR, AXL, CYP1A1, CYP1B1, FABP4, FLT3, IGF1R, KDR, MMP2, RELA, RORC, SRC | 2.99575 |
| [BP] GO:0040012 | regulation of locomotion | ADORA1, ADORA3, APP, CYP19A1, CYP1B1, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.95072 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, HSD17B3, MAOA, XDH | 2.93035 |
| [BP] GO:0032501 | multicellular organismal process | ADORA1, AKR1B1, ALOX5, APP, AR, AXL, CACNA1C, CYP19A1, CYP1A2, CYP1B1, F10, F3, FABP4, IGF1R, MET, MMP1, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC, TOP1 | 2.8956 |
| [BP] GO:1901701 | cellular response to oxygen-containing compound | AKR1B1, APP, AR, AXL, CYP1B1, IGF1R, MMP2, MMP9, RELA, RORC, SRC | 2.87859 |
| [BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, APP, AR, AXL, CA2, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FLT3, HSD17B3, KDR, MAP2K1, MMP9, PIM1, PPARA, RELA, RORC, SRC | 2.87859 |
| [BP] GO:0032787 | None | ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, FABP3, PPARA, PTGES | 2.86669 |
| [BP] GO:0019216 | regulation of lipid metabolic process | ADORA1, CYP1A1, FABP3, FLT3, HCAR2, PPARA, RORC, SRC | 2.83512 |
| [BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, APP, AR, AURKB, AXL, CA2, CA9, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP4, FLT3, FUT7, HSD17B3, KDR, MAP2K1, MET, MMP2, MMP9, PIM1, PPARA, RELA, RORC, SRC | 2.74884 |
| [BP] GO:0000302 | response to reactive oxygen species | AKR1B1, AXL, CYP1B1, MMP9, RELA, SRC | 2.74871 |
| [BP] GO:1901654 | None | AKR1B1, AR, CA9, CSNK2A1, RELA, SRC | 2.69634 |
| [BP] GO:0043410 | positive regulation of MAPK cascade | ADORA1, APP, AR, FLT3, KDR, MAP2K1, MAP3K7, SRC, XDH | 2.66573 |
| [BP] GO:0042542 | response to hydrogen peroxide | AKR1B1, AXL, CYP1B1, RELA, SRC | 2.60496 |
| [BP] GO:0016310 | phosphorylation | APP, AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 2.59398 |
| [BP] GO:0051240 | positive regulation of multicellular organismal process | APP, AR, AXL, CA2, CYP1B1, F3, HCAR2, KDR, MAP2K1, MAP3K7, MET, MMP9, PIM1, RELA, SRC | 2.58368 |
| [BP] GO:0034599 | cellular response to oxidative stress | AKR1B1, AXL, CYP1B1, MMP9, RELA, SRC | 2.51002 |
| [BP] GO:0006805 | xenobiotic metabolic process | CYP1A1, CYP1A2, CYP1B1, CYP2A13, RORC | 2.51002 |
| [BP] GO:0097237 | cellular response to toxic substance | AKR1B1, AXL, CYP1B1, KDR, RELA | 2.40961 |
| [BP] GO:0043393 | regulation of protein binding | APP, AURKB, MET, MMP9, PPARA, SRC | 2.38654 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.38363 |
| [BP] GO:2000021 | regulation of ion homeostasis | ADORA1, CA2, CA7, CACNA1C, KDR, SRC | 2.36181 |
| [BP] GO:0070301 | cellular response to hydrogen peroxide | AKR1B1, AXL, CYP1B1, RELA | 2.35247 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD17B1, HSD17B3 | 2.35247 |
| [BP] GO:0043408 | regulation of MAPK cascade | ADORA1, APP, AR, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, SRC, XDH | 2.34331 |
| [BP] GO:0051896 | regulation of protein kinase B signaling | AXL, F10, F3, MET, SRC, XDH | 2.34083 |
| [BP] GO:0008284 | positive regulation of cell proliferation | AKR1B1, AR, CSNK2A1, F3, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, RELA | 2.31716 |
| [BP] GO:0010038 | response to metal ion | APP, CA2, CYP1A1, CYP1A2, FABP4, MMP9, PTGES | 2.3136 |
| [BP] GO:0030335 | positive regulation of cell migration | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.30757 |
| [BP] GO:0001101 | response to acid chemical | AKR1B1, FABP3, KDR, MMP2, PTGES, RELA, SRC | 2.29439 |
| [BP] GO:0042493 | response to drug | AKR1B1, AXL, CA9, CYP1A1, CYP1B1, FABP3, KDR, RELA, SRC, TOP1 | 2.27216 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.23661 |
| [BP] GO:0080134 | regulation of response to stress | ADORA1, APP, CYP19A1, F3, FABP4, IGF1R, MAP2K1, MAP3K7, MET, MMP2, PPARA, RELA, SRC, XDH | 2.23279 |
| [BP] GO:2000147 | positive regulation of cell motility | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.21441 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1 | 2.19245 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.19245 |
| [BP] GO:0006979 | response to oxidative stress | AKR1B1, APP, AXL, CYP1B1, MMP9, RELA, SRC | 2.14981 |
| [BP] GO:0051272 | positive regulation of cellular component movement | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.14981 |
| [BP] GO:0032847 | regulation of cellular pH reduction | CA2, CA7 | 2.14981 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.14981 |
| [BP] GO:0006811 | None | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, FABP3, PPARA | 2.13933 |
| [BP] GO:0032844 | regulation of homeostatic process | ADORA1, AURKB, CA2, CA7, CACNA1C, HCAR2, KDR, SRC | 2.13083 |
| [BP] GO:1901652 | response to peptide | AKR1B1, APP, FABP3, IGF1R, PPARA, RELA, SRC | 2.11688 |
| [BP] GO:0071407 | cellular response to organic cyclic compound | APP, AR, CYP1A1, CYP1B1, FLT3, RORC, SRC | 2.10422 |
| [BP] GO:0040017 | positive regulation of locomotion | APP, F10, F3, IGF1R, KDR, MET, MMP9, SRC | 2.05741 |
| [BP] GO:0051897 | positive regulation of protein kinase B signaling | AXL, F10, F3, MET, SRC | 2.01329 |
| [CC] GO:0005641 | nuclear envelope lumen | ALOX5, APP, PTGES | 3.48939 |
| [CC] GO:0031233 | None | CA4, F10, F3 | 2.38396 |
| [CC] GO:0016020 | membrane | ACHE, ADORA1, ADORA3, ALOX5, APP, AR, AXL, CA12, CA14, CA2, CA4, CA9, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FLT3, FUT7, HCAR2, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP2, PIM1, PTGES, SRC | 1.79026 |
| [CC] GO:0005886 | plasma membrane | ACHE, ADORA1, ADORA3, APP, AR, AXL, CA12, CA14, CA2, CA4, CA9, CACNA1C, CSNK2A1, F10, F3, FLT3, HCAR2, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP2, PIM1, SRC | 1.77494 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, ALOX5, APP, AR, AURKB, CA1, CA2, CA4, CA5A, CA5B, CA7, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, FABP3, FABP4, FLT3, FUT7, HSD17B1, HSD17B3, KDR, MAOA, MAP2K1, MAP3K7, MMP2, MMP9, PIM1, PTGES, RELA, SRC, TOP1, XDH | 1.65784 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 18.1084 |
| [MF] GO:0046914 | transition metal ion binding | ALOX5, APP, AR, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, MMP1, MMP2, MMP9, PIM1, PPARA, RORC, XDH | 12.93 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 11.758 |
| [MF] GO:0043167 | ion binding | ACHE, ALOX5, APP, AR, AURKB, AXL, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FABP3, FABP4, FLT3, HSD17B1, IGF1R, KDR, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PPARA, PTGES, RELA, RORC, SRC, TOP1, XDH | 11.6554 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 10.5667 |
| [MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, ALOX5, AURKB, AXL, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, F3, FLT3, FUT7, HSD17B1, HSD17B3, IGF1R, KDR, MAOA, MAP2K1, MAP3K7, MET, MMP1, MMP2, MMP9, PIM1, PTGES, SRC, TOP1, XDH | 9.37791 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 6.83747 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 | 6.83747 |
| [MF] GO:0008270 | zinc ion binding | AR, CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PPARA, RORC | 5.38534 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 5.32398 |
| [MF] GO:0005506 | iron ion binding | ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, XDH | 5.01599 |
| [MF] GO:0043169 | cation binding | ACHE, ALOX5, APP, AR, AURKB, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, MAP3K7, MMP1, MMP2, MMP9, PIM1, PPARA, RORC, XDH | 5.01599 |
| [MF] GO:0046872 | metal ion binding | ALOX5, APP, AR, AURKB, CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, CACNA1C, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, F10, MAP3K7, MMP1, MMP2, MMP9, PIM1, PPARA, RORC, XDH | 4.6455 |
| [MF] GO:0020037 | heme binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, SRC | 4.45403 |
| [MF] GO:0008144 | drug binding | ACHE, AURKB, AXL, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, PPARA, SRC, TOP1 | 4.34626 |
| [MF] GO:0046906 | tetrapyrrole binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, SRC | 4.29626 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13 | 4.15216 |
| [MF] GO:0004672 | protein kinase activity | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 4.07933 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 3.98356 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, HSD17B3, MAOA, XDH | 3.67694 |
| [MF] GO:0004713 | protein tyrosine kinase activity | AXL, FLT3, IGF1R, KDR, MAP2K1, MET, SRC | 3.63621 |
| [MF] GO:0048037 | cofactor binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, HSD17B1, PTGES, SRC, XDH | 3.61294 |
| [MF] GO:0004714 | transmembrane receptor protein tyrosine kinase activity | AXL, FLT3, IGF1R, KDR, MET | 3.61294 |
| [MF] GO:0016773 | phosphotransferase activity, alcohol group as acceptor | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 3.45117 |
| [MF] GO:0008395 | steroid hydroxylase activity | CYP19A1, CYP1A1, CYP2A13, CYP2A6 | 3.23052 |
| [MF] GO:0019199 | transmembrane receptor protein kinase activity | AXL, FLT3, IGF1R, KDR, MET | 3.18151 |
| [MF] GO:0016301 | kinase activity | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 3.09628 |
| [MF] GO:0042562 | hormone binding | ACHE, AR, HSD17B1, IGF1R, SHBG | 3.04292 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6 | 2.99046 |
| [MF] GO:0043168 | anion binding | APP, AURKB, AXL, CSNK2A1, F10, F3, FABP3, FABP4, FLT3, HSD17B1, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, PTGES, RELA, SRC, TOP1, XDH | 2.88224 |
| [MF] GO:0008389 | None | CYP2A13, CYP2A6 | 2.80249 |
| [MF] GO:0008289 | lipid binding | AR, AXL, F10, F3, FABP3, FABP4, HSD17B1, PPARA, RORC, SHBG | 2.52785 |
| [MF] GO:0016772 | transferase activity, transferring phosphorus-containing groups | AURKB, AXL, CSNK2A1, FLT3, IGF1R, KDR, MAP2K1, MAP3K7, MET, PIM1, SRC, TOP1 | 2.47071 |
| [MF] GO:0005497 | None | AR, SHBG | 2.14981 |
KEGG Pathways Associated to Targeted Human Proteins
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA5B, CA5A, CA2, CA4, CA7, CA6, CA9, CA14 | 19.5677 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | ALOX5, HSD17B1, CYP1A1, CYP1B1, CYP19A1, IGF1R | 6.4556 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD17B1, CYP1A2, CYP1A1, HSD17B3, CYP1B1, CYP19A1 | 6.2328 |
| Bladder cancer_Homo sapiens_hsa05219 | MAP2K1, SRC, MMP1, MMP2, MMP9 | 5.465 |
| Pathways in cancer_Homo sapiens_hsa05200 | AR, MAP2K1, FLT3, MMP1, MMP2, MMP9, MET, RELA, IGF1R | 4.5519 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | MAP2K1, SRC, MMP2, KDR, MMP9, MET, IGF1R | 4.5519 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1 | 4.514 |
| Adherens junction_Homo sapiens_hsa04520 | CSNK2A1, SRC, MAP3K7, MET, IGF1R | 4.514 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | CYP2A6, CYP2A13, CYP1A2, CYP1A1, CYP1B1 | 4.338 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | HCAR2, MAP2K1, ADORA1, CACNA1C, PPARA, RELA | 3.7003 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | MAOA, CYP1A2, CYP1A1, CYP1B1 | 4.2154 |
| Serotonergic synapse_Homo sapiens_hsa04726 | APP, MAP2K1, MAOA, ALOX5, CACNA1C | 3.752 |
| Acute myeloid leukemia_Homo sapiens_hsa05221 | MAP2K1, FLT3, PIM1, RELA | 3.6992 |
| Metabolic pathways_Homo sapiens_hsa01100 | CYP2A6, FUT7, MAOA, ALOX5, HSD17B1, CYP1A2, CYP1A1, HSD17B3, AKR1B1, CYP19A1, XDH, PTGES | 3.0221 |
| Prostate cancer_Homo sapiens_hsa05215 | AR, MAP2K1, RELA, IGF1R | 3.0202 |
| GnRH signaling pathway_Homo sapiens_hsa04912 | MAP2K1, SRC, MMP2, CACNA1C | 3.0075 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | MMP2, PIM1, F3, RELA | 2.8989 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, MMP1, PPARA | 3.3995 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | MAP2K1, SRC, MMP2, MMP9 | 2.9115 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | FLT3, MMP9, MET, RELA, IGF1R | 2.9666 |
| Focal adhesion_Homo sapiens_hsa04510 | MAP2K1, SRC, KDR, MET, IGF1R | 2.7967 |
| Rap1 signaling pathway_Homo sapiens_hsa04015 | MAP2K1, SRC, KDR, MET, IGF1R | 2.7469 |
| TNF signaling pathway_Homo sapiens_hsa04668 | MAP2K1, MMP9, MAP3K7, RELA | 2.7959 |
| Ras signaling pathway_Homo sapiens_hsa04014 | MAP2K1, KDR, MET, RELA, IGF1R | 2.6356 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | MAP2K1, ADORA3, ADORA1, RELA | 2.6876 |
| Hepatitis B_Homo sapiens_hsa05161 | MAP2K1, SRC, MMP9, RELA | 2.4147 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP2A6, CYP1A2, XDH | 5.2108 |
| VEGF signaling pathway_Homo sapiens_hsa04370 | MAP2K1, SRC, KDR | 2.4336 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | MAP2K1, ADORA3, ADORA1, CACNA1C | 2.294 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | MAP2K1, PIM1, CYP1B1, MMP9, MET | 2.2506 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | MAP2K1, KDR, MET, RELA, IGF1R | 2.0222 |
| Central carbon metabolism in cancer_Homo sapiens_hsa05230 | MAP2K1, FLT3, MET | 2.36 |
| Melanoma_Homo sapiens_hsa05218 | MAP2K1, MET, IGF1R | 2.3281 |
| Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | SRC, MET, RELA | 2.3556 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | MAP2K1, SRC, RELA | 2.3234 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP2A6, CYP1A2, CYP1A1 | 2.3837 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP2A6, MAOA, CYP1A2 | 2.3509 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, MAP2K1, CACNA1C | 1.8871 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | MAP2K1, RELA, IGF1R | 1.9473 |
| Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | MAP2K1, MAP3K7, RELA | 1.9333 |
| T cell receptor signaling pathway_Homo sapiens_hsa04660 | MAP2K1, MAP3K7, RELA | 1.9462 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | MAP2K1, CACNA1C, MAP3K7, RELA | 1.7476 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, MAP3K7, RELA | 2.0514 |
| Endocytosis_Homo sapiens_hsa04144 | SRC, KDR, MET, IGF1R | 1.7333 |
| Toxoplasmosis_Homo sapiens_hsa05145 | ALOX5, MAP3K7, RELA | 1.8225 |
| Oocyte meiosis_Homo sapiens_hsa04114 | AR, MAP2K1, IGF1R | 1.7817 |
| Osteoclast differentiation_Homo sapiens_hsa04380 | MAP2K1, MAP3K7, RELA | 1.7245 |
| Measles_Homo sapiens_hsa05162 | CSNK2A1, MAP3K7, RELA | 1.6975 |
| Oxytocin signaling pathway_Homo sapiens_hsa04921 | MAP2K1, SRC, CACNA1C | 1.5447 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1, MAP3K7, RELA | 1.4489 |
| Chemokine signaling pathway_Homo sapiens_hsa04062 | MAP2K1, SRC, RELA | 1.4489 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, MAP3K7, RELA | 1.4001 |
| Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | FLT3, KDR, MET | 1.1438 |
| Glioma_Homo sapiens_hsa05214 | MAP2K1, IGF1R | 1.4489 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.5025 |
| Long-term depression_Homo sapiens_hsa04730 | MAP2K1, IGF1R | 1.4612 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1, CACNA1C | 1.4489 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | MAP2K1, IGF1R | 1.2176 |
| Insulin resistance_Homo sapiens_hsa04931 | PPARA, RELA | 1.1438 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | MAP2K1, RELA | 1.0889 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | MAP2K1, SRC | 1.0918 |
| Apoptosis_Homo sapiens_hsa04210 | MAP2K1, RELA | 1.0036 |
| ErbB signaling pathway_Homo sapiens_hsa04012 | MAP2K1, SRC | 1.2931 |
| Leukocyte transendothelial migration_Homo sapiens_hsa04670 | MMP2, MMP9 | 1.0918 |
| Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | RELA, IGF1R | 1.2455 |
| Long-term potentiation_Homo sapiens_hsa04720 | MAP2K1, CACNA1C | 1.4489 |
| AMPK signaling pathway_Homo sapiens_hsa04152 | MAP3K7, IGF1R | 1.0684 |
| B cell receptor signaling pathway_Homo sapiens_hsa04662 | MAP2K1, RELA | 1.4101 |
| Pancreatic cancer_Homo sapiens_hsa05212 | MAP2K1, RELA | 1.4489 |
| Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | RORC, RELA | 1.4489 |
| FoxO signaling pathway_Homo sapiens_hsa04068 | MAP2K1, IGF1R | 1.0336 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA, RELA | 0.9638 |
| Vascular smooth muscle contraction_Homo sapiens_hsa04270 | MAP2K1, CACNA1C | 1.0889 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1, SRC | 1.0044 |
| Dopaminergic synapse_Homo sapiens_hsa04728 | MAOA, CACNA1C | 1.0475 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | MAP2K1, RELA | 1.4101 |
| Hepatitis C_Homo sapiens_hsa05160 | PPARA, RELA | 1.0336 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | MAP2K1, IGF1R | 1.002 |
| NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | MAP3K7, RELA | 1.4958 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1, MAP3K7 | 1.002 |
| Arachidonic acid metabolism_Homo sapiens_hsa00590 | ALOX5, PTGES | 1.4489 |
| Renal cell carcinoma_Homo sapiens_hsa05211 | MAP2K1, MET | 1.4489 |
| HTLV-I infection_Homo sapiens_hsa05166 | RELA | 0.2972 |
| GABAergic synapse_Homo sapiens_hsa04727 | SRC, CACNA1C | 1.2931 |
| Amphetamine addiction_Homo sapiens_hsa05031 | MAOA, CACNA1C | 1.4489 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA, RELA | 1.4257 |
| Shigellosis_Homo sapiens_hsa05131 | SRC, RELA | 1.4489 |
| Gap junction_Homo sapiens_hsa04540 | MAP2K1, SRC | 1.2931 |
| Alzheimer's disease_Homo sapiens_hsa05010 | APP, CACNA1C | 0.9101 |
| Leishmaniasis_Homo sapiens_hsa05140 | MAP3K7, RELA | 1.4101 |
| Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | SRC, MET | 1.3679 |
| Influenza A_Homo sapiens_hsa05164 | MAP2K1, RELA | 0.8962 |
| Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | MAP2K1, SRC | 0.7849 |
| Alcoholism_Homo sapiens_hsa05034 | MAP2K1, MAOA | 0.8918 |
| Tuberculosis_Homo sapiens_hsa05152 | SRC, RELA | 0.8918 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | SRC, RELA | 0.8119 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.415 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1 | 0.6486 |
| Calcium signaling pathway_Homo sapiens_hsa04020 | CACNA1C | 0.4101 |
| Cocaine addiction_Homo sapiens_hsa05030 | MAOA, RELA | 1.5977 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F10, F3 | 1.3634 |
| RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | MAP3K7, RELA | 1.4257 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | PIM1 | 0.4495 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | CACNA1C | 0.4699 |
| Phospholipase D signaling pathway_Homo sapiens_hsa04072 | MAP2K1 | 0.4769 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | MAP2K1 | 0.4869 |
| Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | MAP2K1 | 0.4946 |
| Axon guidance_Homo sapiens_hsa04360 | MET | 0.5141 |
| Platelet activation_Homo sapiens_hsa04611 | SRC | 0.5261 |
| Glutamatergic synapse_Homo sapiens_hsa04724 | CACNA1C | 0.5484 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | CYP2A6, XDH | 1.6423 |
| Melanogenesis_Homo sapiens_hsa04916 | MAP2K1 | 0.5882 |
| Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | RELA | 0.5799 |
| Amoebiasis_Homo sapiens_hsa05146 | RELA | 0.5882 |
| Choline metabolism in cancer_Homo sapiens_hsa05231 | MAP2K1 | 0.5882 |
| Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | MAP2K1 | 0.5935 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.5882 |
| Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | SRC | 0.5882 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.5913 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.5902 |
| Circadian entrainment_Homo sapiens_hsa04713 | CACNA1C | 0.5913 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.5988 |
| Rheumatoid arthritis_Homo sapiens_hsa05323 | MMP1 | 0.6 |
| Hematopoietic cell lineage_Homo sapiens_hsa04640 | FLT3 | 0.6 |
| Taste transduction_Homo sapiens_hsa04742 | CACNA1C | 0.6094 |
| Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | CACNA1C | 0.5882 |
| Dilated cardiomyopathy_Homo sapiens_hsa05414 | CACNA1C | 0.6 |
| Insulin secretion_Homo sapiens_hsa04911 | CACNA1C | 0.6052 |
| Salmonella infection_Homo sapiens_hsa05132 | RELA | 0.6052 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6 |
| Aldosterone synthesis and secretion_Homo sapiens_hsa04925 | CACNA1C | 0.6094 |
| Small cell lung cancer_Homo sapiens_hsa05222 | RELA | 0.6052 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6094 |
| Hypertrophic cardiomyopathy (HCM)_Homo sapiens_hsa05410 | CACNA1C | 0.6094 |
| Cardiac muscle contraction_Homo sapiens_hsa04260 | CACNA1C | 0.6207 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6347 |
| Pertussis_Homo sapiens_hsa05133 | RELA | 0.6326 |
| Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | MAP2K1 | 0.6544 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6442 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC)_Homo sapiens_hsa05412 | CACNA1C | 0.6347 |
| Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | IGF1R | 0.6751 |
| Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | RELA | 0.6751 |
| Colorectal cancer_Homo sapiens_hsa05210 | MAP2K1 | 0.6807 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B1 | 0.697 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | MAP2K1 | 0.7144 |
| Legionellosis_Homo sapiens_hsa05134 | RELA | 0.7181 |
| Endometrial cancer_Homo sapiens_hsa05213 | MAP2K1 | 0.7371 |
| Malaria_Homo sapiens_hsa05144 | MET | 0.754 |
| Arginine and proline metabolism_Homo sapiens_hsa00330 | MAOA | 0.7493 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.1061 |
| Type II diabetes mellitus_Homo sapiens_hsa04930 | CACNA1C | 0.7585 |
| Prion diseases_Homo sapiens_hsa05020 | MAP2K1 | 0.8693 |
| Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | MAOA | 0.8219 |
| Thyroid cancer_Homo sapiens_hsa05216 | MAP2K1 | 0.9101 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B1 | 0.9052 |
| Dorso-ventral axis formation_Homo sapiens_hsa04320 | MAP2K1 | 0.9278 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8962 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.9101 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | MAOA | 0.8693 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B1 | 0.8918 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B1 | 0.8614 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.9348 |
| Circadian rhythm_Homo sapiens_hsa04710 | RORC | 0.9052 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.9278 |
| Histidine metabolism_Homo sapiens_hsa00340 | MAOA | 0.9638 |
| Phenylalanine metabolism_Homo sapiens_hsa00360 | MAOA | 1.0668 |
Target Exprsssion in Healthy Human Tissues (protein & mRNA level)
Protein expression data was from the "Human Proteome Map" datasetmRNA expression data was from the "GTEx" dataset
Average Target Expression (Fold Change) in Multiple Disease Conditions
Fold Change with Corresponding Normal SamplesClick each cell within the heatmap to access gene expression of individual patient samples